2026 Pudong Special Program for High-Quality Development of Biopharma Industry Kicks Off: Training Session Highlights Key Points for Applicants

(Source:WaigaoqiaoWindow)

To accelerate the high-quality development of the biopharmaceutical industry in Pudong New Area and help enterprises accurately graspSpecial Declaration Policy for Promoting the High-Quality Development of the Biomedical Industry in Pudong New Area in 2026. On the afternoon of May 11, a special declaration training event, hosted by the Science and Technology and Economy Committee of Pudong New Area and organized by Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd., a subsidiary of Waigaoqiao Group, was successfully held at the headquarters of Waigaoqiao Group. The event attracted Medtronic, Novartis, Huiyong, and Huanma.etc.Nearby Area60Representatives from China's key biopharmaceutical enterprises attended.

Focus on Policy Priorities to Help Enterprises Accurately Submit Applications

This training focuses on "2026 Pudong New Area Special Application Guidelines for Promoting High-Quality Development of the Biomedical IndustryThe Biomedical Materials Department of the Science and Economy Commission of Pudong New Area provides specific interpretations of the four thematic directions in the application requirements.Including: supporting the R&D of innovative drugs and devices, promoting the new model of contract research and production organizations, supporting the internationalization of innovative drug and device products, and providing matching support for municipal projects.

At the training session, the District Science and Economy Commission provided a detailed explanation of key aspects such as application eligibility, criteria, material preparation, timelines, and the online application process, based on common issues encountered during actual enterprise applications. This helped companies clarify their approach and improve the quality of their submissions.

Q&A InteractionPragmaticServices are more down-to-earth

During the interactive Q&A session, corporate representatives focused on clinical research for Class I new drugs, registration of Class III medical devices,Active questioning on specific issues such as FDA/EMA international certification and contract manufacturing.The experts from the District Science and Economy Commission patiently answered one by one.The atmosphere of on-site communication was warm, and enterprise representatives expressed that the training content"Chock-full of valuable content,"Provided effective guidance for subsequent enterprise applications.

Extended Service ChainBoosting High-Quality Development in the Industry

As the organizer of this event, Waigaoqiao Biomedical Company will continue to ensure the implementation of policies."Running Partner",On the basis of training, further extend the service chain in policy对接, application guidance, resource linking, and process tracking.Provide more precise and efficient support services to help enterprises make full and good use of policies at all levels., promoting the landing and growth of more high-quality projects in the Waigaoqiao area.Continuously optimize the industrial ecological environment,Enhance service capabilities to contribute greater strength to the high-quality development of the biopharmaceutical industry in Pudong New Area.